#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Isodicentric chromosome 15 syndrome Chondrosarcoma Immune-mediated myasthenia gravis Toxic epidermal necrolysis Alagille syndrome Astrocytoma Bronchopulmonary dysplasia Multiple system atrophy Primary mediastinal large B-cell lymphoma Eosinophilic granulomatosis with polyangiitis Synovitis Polycythaemia vera Chronic graft versus host disease in intestine Cholangiosarcoma Penile squamous cell carcinoma More trials…

    Learn about Rare Diseases

    Hereditary angioedema – Life with Disease Friedreich’s ataxia – Diagnostics Stevens-Johnson syndrome – Diagnostics Niemann-Pick disease Erdheim-Chester disease – Treatment Waldenstrom’s macroglobulinaemia refractory Mitochondrial myopathy – Treatment Ewing’s sarcoma metastatic – Life with Disease Chondrosarcoma – Treatment Hereditary ataxia – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Caspofungin Acetate Setanaxib Rbl012.2 RO7284755 SRSD107 Asundexian Imiquimod Inclisiran Sodium Ptc518 Tak-280 Trimetazidine Dihydrochloride HRS 9531 Rifamycin Sodium Emtricitabine TTX-381 Timolol Omp12 Abt-494 Serine Teprenone More therapies…

    Learn about Your Condition

    Rectal cancer recurrent Sarcoidosis Mite allergy Breast cancer stage III Insomnia Bacterial prostatitis Uterine leiomyosarcoma Osteomyelitis acute Small fibre neuropathy Urinary tract infection Hypertrophic cardiomyopathy Deafness traumatic Vestibular disorder Endotracheal intubation Inguinal hernia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Bladder cancer

  • Study of Visugromab and Nivolumab for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Refuse Cisplatin Chemotherapy

    Not recruiting

    2 1 1
    Investigated Drugs:
    • VISUGROMAB
    • Nivolumab
    • Sodium Chloride
    Italy

  • Study on Erdafitinib and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin Treatment

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Cetrelimab
    • Erdafitinib
    France Italy Spain

  • Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Gallbladder cancer
    • B-cell lymphoma
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Cyc140 Monohydrochloride Monohydrate
    Spain

  • Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Poloxamer 407
    Bulgaria Estonia Latvia Romania Spain

  • Study of Nivolumab alone or combined with Ipilimumab for patients with advanced solid tumors (breast, gastric, pancreatic, lung, bladder, or ovarian cancer)

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma
    • Ovarian cancer
    • Breast cancer
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    Germany

  • Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Pembrolizumab
    Belgium Denmark France Germany Hungary Ireland +4
Previous Page
1 … 3 4 5 6 7 … 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!